参考文献/References:
[1]Beck DB,Ferrada MA,Sikora KA,et al.Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease[J].N Engl J Med,2020,383(27):2628-2638.[2]Stubbins RJ,Cherniawsky H,Chen LYC,et al.Innovations in genomics for undiagnosed diseases: vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome[J].CMAJ,2022,194(14):E524-E527.[3]Kosmider O,Possémé C,Templé M,et al.VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation[J].Nat Commun,2024,15(1):910.[4]Huang H,Zhang W,Cai W,et al.VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder[J].Exp Hematol Oncol,2021,10(1):23.[5]Poulter J,UKGCA/VEXAS Consortium,Morgan A,et al.A High-Throughput Amplicon Screen for Somatic UBA1 Variants in Cytopenic and Giant Cell Arteritis Cohorts[J].J Clin Immunol,2022,42(5):947-951.[6]Comont T,Heiblig M,Dion J,et al.Azacitidine (AZA) for Patients with Vexas and Myelodysplastic Syndrome (MDS): Data from the French Vexas Registry[J].Blood,2021,138:3689.[7]Heiblig M,Ferrada MA,Gerfaud-Valentin M,et al.Clinical efficacy of JAK inhibitors in patients with VEXAS syndrome: a multicenter retrospective study[J].Blood,2021,138:2608.[8]van Leeuwen-Kerkhoff N,de Witte MA,Heijstek MW,et al.Case report: Up-front allogeneic stem cell transplantation in a patient with the VEXAS syndrome[J].Br J Haematol,2022,199(3):e12-e15.[9]Barba T,Jamilloux Y,Durel CA,et al.VEXAS syndrome in a woman[J].Rheumatology (Oxford),2021,60(11):e402-e403.[10]Beck DB,Werner A,Kastner DL,et al.Disorders of ubiquitylation: unchained inflammation[J].Nat Rev Rheumatol,2022,18(8):435-447.[11]Nune A,Iyengar KP,Barman B,et al.The VEXAS syndrome from rheumatology perspective: genomic DNA sequencing as available blueprint for diagnosing rheumatic diseases with overlapping haematological or dermatological findings[J].Clin Rheumatol,2022,41(9):2917-2918.[12]Argobi Y.VEXAS syndrome with cutaneous nodules[J].Dermatol Reports,2021,14(2):9414.[13]Lee SMS,Fan BE,Lim JH,et al.A case of VEXAS syndrome manifesting as Kikuchi-Fujimoto disease, relapsing polychondritis, venous thromboembolism and macrocytic anaemia[J].Rheumatology (Oxford),2021,60(9):e304-e306.[14]Ramon A,Greigert H,Ornetti P,et al.Mimickers of Large Vessel Giant Cell Arteritis[J].J Clin Med,2022,11(3):495.[15]Lacombe V,Beucher A,Urbanski G,et al.Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome[J].Exp Hematol Oncol,2022,11(1):6.[16]Obiorah IE,Patel BA,Groarke EM,et al.Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1[J].Blood Adv,2021,5(16):3203-3215.[17]Rossignol J,Marzac C,Dellal A,et al.UBA1 gene mutation in giant cell arteritis[J].Clin Rheumatol,2022,41(4):1257-1259.[18]Horton RK,Zheng G.A case of VEXAS syndrome with subtle morphologic findings[J].Blood,2021,138(15):1378.[19]L?觟tscher F,Pop R,Seitz P,et al.Spectrum of Large- and Medium-Vessel Vasculitis in Adults: Neoplastic, Infectious, Drug-Induced, Autoinflammatory, and Primary Immunodeficiency Diseases[J].Curr Rheumatol Rep,2022,24(10):293-309.[20]Grey A,Cheong PL,Lee FJ,et al.A Case of VEXAS Syndrome Complicated by Hemophagocytic Lymphohistiocytosis[J].J Clin Immunol,2021,41(7):1648-1651.[21]Seitz L,Seitz P,Pop R,et al.Spectrum of Large and Medium Vessel Vasculitis in Adults: Primary Vasculitides, Arthritides, Connective Tissue, and Fibroinflammatory Diseases[J].Curr Rheumatol Rep,2022,24(11):352-370.[22]Oo TM,Koay JTJ,Lee SF,et al.Thrombosis in VEXAS syndrome[J].J Thromb Thrombolysis,2022,53(4):965-970.[23]Kouranloo K,Ashley A,Zhao SS,et al.Pulmonary manifestations in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: a systematic review[J].Rheumatol Int,2023,43(6):1023-1032.[24]Bourbon E,Heiblig M,Gerfaud Valentin M,et al.Therapeutic options in VEXAS syndrome: insights from a retrospective series[J].Blood,2021,137(26):3682-3684.[25]Staels F,Betrains A,Woei-A-Jin FJSH,et al.Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome[J].Front Immunol,2021,12:678927.[26]Georgin-Lavialle S,Terrier B,Guedon AF,et al.Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients[J].Br J Dermatol,2022,186(3):564-574.[27]Lytle A,Bagg A.VEXAS:a vivid new syndrome associated with vacuoles in various hematopoietic cells[J].Blood,2021,137(26):3690.[28]Gurnari C,Pagliuca S,Durkin L,et al.Vacuolization of hematopoietic precursors: an enigma with multiple etiologies[J].Blood,2021,137(26):3685-3689.[29]Himmelmann A,Brücker R.The VEXAS Syndrome: Uncontrolled Inflammation and Macrocytic Anaemia in a 77-Year-Old Male Patient[J].Eur J Case Rep Intern Med,2021,8(4):002484.[30]Stubbins RJ.Lost in translation: cytoplasmic UBA1 and VEXAS syndrome[J].Blood,2022,140(13):1455-1457.[31]Poulter JA,Savic S.Genetics of somatic auto-inflammatory disorders[J].Semin Hematol,2021,58(4):212-217.[32]Wilke MVMB,Morava-Kozicz E,Koster MJ,et al.Exome sequencing can misread high variant allele fraction of somatic variants in UBA1 as hemizygous in VEXAS syndrome: a case report[J].BMC Rheumatol,2022,6(1):54.[33]Boyadzhieva Z,Ruffer N,K?觟tter I,et al.How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies[J].Rheumatology (Oxford),2023,62(11):3518-3525.[34]Grayson PC,Patel BA,Young NS.VEXAS syndrome[J].Blood,2021,137(26):3591-3594.[35]Heiblig M,Ferrada MA,Koster MJ,et al.Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study[J].Blood,2022,140(8):927-931.